| Primary |
| Product Used For Unknown Indication |
33.4% |
| Prostate Cancer |
32.5% |
| Prostate Cancer Metastatic |
14.3% |
| Pain |
4.2% |
| Hypertension |
3.0% |
| Blood Pressure |
2.4% |
| Cardiac Disorder |
1.3% |
| Metastases To Bone |
1.1% |
| Diabetes Mellitus |
1.0% |
| Depression |
0.9% |
| Fluid Retention |
0.7% |
| Ill-defined Disorder |
0.7% |
| Constipation |
0.7% |
| Blood Cholesterol |
0.7% |
| Nervousness |
0.6% |
| Hormone Therapy |
0.5% |
| Neoplasm Malignant |
0.5% |
| Oedema |
0.5% |
| Cancer Pain |
0.5% |
| Diuretic Therapy |
0.5% |
|
| Death |
19.9% |
| Prostatic Specific Antigen Increased |
11.0% |
| Vomiting |
6.1% |
| Thrombocytopenia |
5.7% |
| Drug Ineffective |
4.9% |
| Myocardial Infarction |
4.7% |
| Nausea |
4.7% |
| Hospitalisation |
4.2% |
| Weight Decreased |
4.0% |
| Oedema Peripheral |
3.8% |
| Pain |
3.6% |
| Disease Progression |
3.4% |
| Urinary Tract Infection |
3.4% |
| Pneumonia |
3.2% |
| Weight Increased |
3.2% |
| Blood Alkaline Phosphatase Increased |
3.0% |
| Pulmonary Embolism |
3.0% |
| Renal Failure |
3.0% |
| Fatigue |
2.7% |
| Pleural Effusion |
2.7% |
|
| Secondary |
| Prostate Cancer |
24.8% |
| Product Used For Unknown Indication |
22.6% |
| Prostate Cancer Metastatic |
20.8% |
| Multiple Myeloma |
6.0% |
| Blood Pressure |
3.8% |
| Fluid Retention |
3.1% |
| Pain |
3.0% |
| Hypertension |
2.0% |
| Metastases To Bone |
2.0% |
| Feeling Jittery |
1.8% |
| Nervousness |
1.8% |
| Oedema |
1.8% |
| Type 2 Diabetes Mellitus |
1.6% |
| Cancer Pain |
1.0% |
| Cardiac Disorder |
0.7% |
| Pain Management |
0.7% |
| Hormone Therapy |
0.6% |
| Nausea |
0.6% |
| Depression |
0.5% |
| Diabetes Mellitus |
0.5% |
|
| Vomiting |
7.8% |
| Liver Function Test Abnormal |
6.9% |
| Syncope |
6.9% |
| Prostatic Specific Antigen Increased |
6.0% |
| Weight Increased |
6.0% |
| Alanine Aminotransferase Increased |
5.2% |
| Fatigue |
5.2% |
| Pain |
5.2% |
| Thrombocytopenia |
5.2% |
| Vertigo |
5.2% |
| Chest Discomfort |
4.3% |
| Confusional State |
4.3% |
| Joint Swelling |
4.3% |
| Liver Injury |
4.3% |
| Pulmonary Embolism |
4.3% |
| Somnolence |
4.3% |
| Weight Decreased |
4.3% |
| Death |
3.4% |
| Hypokalaemia |
3.4% |
| Inappropriate Schedule Of Drug Administration |
3.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
55.7% |
| Prostate Cancer |
20.3% |
| Prostate Cancer Metastatic |
5.8% |
| Metastases To Bone |
3.7% |
| Pain |
1.9% |
| Diabetes Mellitus |
1.5% |
| Prophylaxis |
1.5% |
| Bone Pain |
1.0% |
| Gastrooesophageal Reflux Disease |
1.0% |
| Type 2 Diabetes Mellitus |
1.0% |
| Antiandrogen Therapy |
0.8% |
| Blood Pressure |
0.8% |
| Constipation |
0.8% |
| Nausea |
0.8% |
| Anaemia |
0.6% |
| Atrial Fibrillation |
0.6% |
| Hyperglycaemia |
0.6% |
| Hypertension |
0.6% |
| Rash |
0.6% |
| Small Intestinal Obstruction |
0.6% |
|
| Osteonecrosis Of Jaw |
13.0% |
| Prostate Cancer |
13.0% |
| Death |
8.7% |
| Hypokalaemia |
7.2% |
| Malignant Neoplasm Progression |
5.8% |
| Prostatic Specific Antigen Increased |
5.8% |
| Vomiting |
5.8% |
| Liver Function Test Abnormal |
4.3% |
| Pain In Extremity |
4.3% |
| Prostate Cancer Metastatic |
4.3% |
| Renal Failure Acute |
4.3% |
| Blood Urine Present |
2.9% |
| Hot Flush |
2.9% |
| Metastases To Bone |
2.9% |
| Nausea |
2.9% |
| Overdose |
2.9% |
| Pulmonary Embolism |
2.9% |
| Therapeutic Response Delayed |
2.9% |
| Blood Glucose Increased |
1.4% |
| Blood Phosphorus Decreased |
1.4% |
|
| Interacting |
| Product Used For Unknown Indication |
50.0% |
| Breast Cancer Metastatic |
25.0% |
| Tuberculosis |
25.0% |
|
| Nausea |
66.7% |
| Drug Interaction |
33.3% |
|
